Skip to main content
SpringerLink
Log in

Current Status of Renal Transplantation

  • Protocol
Transplantation Immunology

Part of the book series: Methods In Molecular Biology™ ((MIMB,volume 333))

Abstract

Renal transplantation is the best treatment for most patients with end-stage renal failure. It markedly improves quality of life and in some cases increases life expectancy. Advances in immunosuppression and other areas of practice have led to an incremental improvement in outcome; 1- and 5-yr graft survival after cadaveric renal transplantation is now around 90 and 70%, respectively. This success has led to increased demand for transplantation that cannot be met by cadaveric heart-beating donors, numbers of which have remained relatively static. Increasing use is now being made of kidneys from so-called “marginal” or “extended criteria” cadaveric donors and from non-heartbeating donors. More reliance is also being placed on living kidney donation, which accounts for around 25% of kidney transplants in the United Kingdom and 50% of transplants in the United States. Much effort in renal transplantation is now being directed toward improving long-term outcomes. This chapter provides an overview of these and other issues in renal transplantation, focusing on some of the topics of current interest.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bradley J. A. and Hamilton D. N. H. (2001) Organ transplantation: an historical perspective, in Transplantation Surgery (Hakim N. S. and Danovitch G. M., eds.), Springer, London, p. 1.

    Google Scholar 

  2. Evans R. W., Manninen D. L., Garrison L. P., Jr., et al. (1985) The quality of life of patients with end-stage renal disease. N. Engl. J. Med. 312, 553–559.

    CAS  PubMed  Google Scholar 

  3. Valderrabano F., Jofre R., and Lopez-Gomez J. M. (2001) Quality of life in endstage renal disease patients. Am. J. Kidney Dis. 38, 443–464.

    CAS  PubMed  Google Scholar 

  4. Wolfe R. A., Ashby V. B., Milford E. L., et al. (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 341, 1725–1730.

    CAS  PubMed  Google Scholar 

  5. Eggers P. (1992) Comparison of treatment costs between dialysis and transplantation. Semin. Nephrol. 12, 284–289.

    CAS  PubMed  Google Scholar 

  6. Croxson B. E. and Ashton T. (1990) A cost effectiveness analysis of the treatment of end stage renal failure. NZ Med. J. 103, 171–174.

    CAS  Google Scholar 

  7. Morris P. J. (2001) Kidney Transplantation. Principles and Practice, W.B.Saunders, Philadelphia.

    Google Scholar 

  8. Hariharan S., Johnson C. P., Bresnahan B. A., Taranto S. E., McIntosh M. J., and Stablein D. (2000) Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. 342, 605–612.

    CAS  PubMed  Google Scholar 

  9. Hariharan S., McBride M. A., Cherikh W. S., Tolleris C. B., Bresnahan B. A., and Johnson C. P. (2002) Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 62, 311–318.

    PubMed  Google Scholar 

  10. Pascual M., Theruvath T., Kawai T., Tolkoff-Rubin N., and Cosimi A. B. (2002) Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med. 346, 580–590.

    PubMed  Google Scholar 

  11. Monaco A. P., Burke J. F. Jr., Ferguson R. M., et al. (1999) Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am. J. Kidney Dis. 33, 150–160.

    CAS  PubMed  Google Scholar 

  12. Opelz G. (2000) Factors influencing long-term graft loss. The Collaborative Transplant Study. Transplant. Proc. 32, 647–649.

    CAS  PubMed  Google Scholar 

  13. Denton M. D. and Singh A. K. (2000) Recurrent and de novo glomerulonephritis in the renal allograft. Semin. Nephrol. 20, 164–175.

    CAS  PubMed  Google Scholar 

  14. Briggs J. D. (2001) Causes of death after renal transplantation. Nephrol. Dial. Transplant. 16, 1545–1549.

    CAS  PubMed  Google Scholar 

  15. Papalois V. E., Moss A., Gillingham K. J., Sutherland D. E., Matas A. J., and Humar A. (2000) Pre-emptive transplants for patients with renal failure: an argument against waiting until dialysis. Transplantation 70, 625–631.

    CAS  PubMed  Google Scholar 

  16. White S. A., Nicholson M. L., and London N. J. (1999) Vascularized pancreas allotransplantation-clinical indications and outcome. Diabet. Med. 16, 533–534.

    CAS  PubMed  Google Scholar 

  17. Roodnat J. I., Zietse R., Mulder P. G., Rischen-Vos J., van Gelder T., Ijzermans J. N., and Weimar W. (1999) The vanishing importance of age in renal transplantation. Transplantation 67, 576–580.

    CAS  PubMed  Google Scholar 

  18. Schaubel D., Desmeules M., Mao Y., Jeffery J., and Fenton S. (1995) Survival experience among elderly end-stage renal disease patients. A controlled comparison of transplantation and dialysis. Transplantation 60, 1389–1394.

    CAS  PubMed  Google Scholar 

  19. Kasiske B. L., Cangro C. B., Hariharan S., et al.; American Society of Transplantation (2002) The evaluation of renal transplantation candidates: clinical practice guidelines. Am. J. Transplant. 1(Suppl. 2), 3–95.

    Google Scholar 

  20. (1995) Criteria for the diagnosis of brain stem death. Review by a working group convened by the Royal College of Physicians and endorsed by the Conference of Medical Royal Colleges and their Faculties in the United Kingdom. J. R. Coll. Physicians Lond. 29, 381–382.

    Google Scholar 

  21. Wijdicks E. F. (2001) The diagnosis of brain death. N. Engl. J. Med. 344, 1215–1221.

    CAS  PubMed  Google Scholar 

  22. Ojo A. O., Hanson J.A., Meier-Kriesche H., et al. (2001) Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and waitlisted transplant candidates. J. Am. Soc. Nephrol. 12, 589–597.

    CAS  PubMed  Google Scholar 

  23. Jerius J. T., Taylor R. J., Murillo D., and Leone J. P. (2000) Double renal transplants from marginal donors: 2-year results. J. Urol. 163, 423–425.

    CAS  PubMed  Google Scholar 

  24. Remuzzi G., Grinyo J., Ruggenenti P., et al. (1999) Early experience with dual kidney transplantation in adults using expanded donor criteria. Double Kidney Transplant Group (DKG). J. Am. Soc. Nephrol. 10, 2591–2598.

    CAS  PubMed  Google Scholar 

  25. Nyberg S. L., Matas A. J., Kremers W. K., et al. (2003) Improved scoring system to assess adult donors for cadaver renal transplantation. Am. J. Transplant. 3, 715–721.

    PubMed  Google Scholar 

  26. Perico N., Ruggenenti P., Scalamogna M., Locatelli G., and Remuzzi G. (2002) One or two marginal organs for kidney transplantation?. Transplant. Proc. 34, 3091–3096.

    CAS  PubMed  Google Scholar 

  27. Persson M. O., Persson N. H., Kallen R., Ekberg H., and Hermeren G. (2002) Kidneys from marginal donors: views of patients on informed consent. Nephrol. Dial. Transplant. 17, 1497–1502.

    PubMed  Google Scholar 

  28. Terasaki P. I., Cecka J. M., Gjertson D. W., and Takemoto S. (1995) High survival rates of kidney transplants from spousal and living unrelated donors. N. Engl. J. Med. 333, 333–336.

    CAS  PubMed  Google Scholar 

  29. Najarian J. S., Chavers B. M., McHugh L. E., and Matas A. J. (1992) 20 years or more of follow-up of living kidney donors. Lancet 340, 807–810.

    CAS  PubMed  Google Scholar 

  30. Kasiske B. L., Ma J. Z., Louis T. A., and Swan S. K. (1995) Long-term effects of reduced renal mass in humans. Kidney Int. 48, 814–819.

    CAS  PubMed  Google Scholar 

  31. (2000). UK Guidelines for Living Donor Kidney Transplantation, British Transplantation Society London, p. 1.

    Google Scholar 

  32. Ratner L. E., Ciseck L. J., Moore R. G., Cigarroa F. G., Kaufman H. S., and Kavoussi L. R. (1995) Laparoscopic live donor nephrectomy. Transplantation 60, 1047–1049.

    CAS  PubMed  Google Scholar 

  33. Waller J. R., Hiley A. L., Mullin E. J., Veitch P. S., and Nicholson M. L. (2002) Living kidney donation: a comparison of laparoscopic and conventional open operations. Postgrad. Med. J. 78, 153–157.

    CAS  PubMed  Google Scholar 

  34. Ratner L. E., Montgomery R. A., and Kavoussi L. R. (1999) Laparoscopic live donor nephrectomy: the four year Johns Hopkins University experience. Nephrol. Dial. Transplant. 14, 2090–2093.

    CAS  PubMed  Google Scholar 

  35. Velidedeoglu E., Williams N., Brayman K. L., et al. (2002) Comparison of open, laparoscopic, and hand-assisted approaches to live-donor nephrectomy. Transplantation 74, 169–172.

    PubMed  Google Scholar 

  36. Lind M. Y., Ijzermans J. N., and Bonjer H. J. (2002) Open vs. laparoscopic donor nephrectomy in renal transplantation. BJU Int. 89, 162–168.

    CAS  PubMed  Google Scholar 

  37. Kuo P. C. and Johnson L. B. (2000) Laparoscopic donor nephrectomy increases the supply of living donor kidneys: a center-specific microeconomic analysis. Transplantation 69, 2211–2213.

    CAS  PubMed  Google Scholar 

  38. Kootstra G. (1995) Statement on non-heart-beating donor programs. Transplant Proc. 27, 2965–2965.

    CAS  PubMed  Google Scholar 

  39. Garcia-Rinaldi R., Lefrak E. A., Defore W. W., et al. (1975) In situ preservation of cadaver kidneys for transplantation: laboratory observations and clinical application. Ann. Surg. 182, 576–584.

    CAS  PubMed  Google Scholar 

  40. Bos M. A. (1995) Legal issues concerning the use of non-heart-beating donors. Transplant. Proc. 27, 2929–2931.

    CAS  PubMed  Google Scholar 

  41. Dunlop P., Varty K., Veitch P. S., Nicholson M. L., and Bell P. R. (1995) Nonheart-beating donors: the Leicester experience. Transplant. Proc. 27, 2940–2941.

    CAS  PubMed  Google Scholar 

  42. Cho Y. W., Terasaki P. I., Cecka J. M., and Gjertson D. W. (1998) Transplantation of kidneys from donors whose hearts have stopped beating. N. Engl. J. Med. 338, 221–225.

    CAS  PubMed  Google Scholar 

  43. Nicholson M. L., Metcalfe M. S., White S. A., et al. (2000) A comparison of the results of renal transplantation from non-heart-beating, conventional cadaveric, and living donors. Kidney Int. 58, 2585–2591.

    CAS  PubMed  Google Scholar 

  44. Weber M., Dindo D., Demartines N., Ambuhl P. M., and Clavien P. A. (2002) Kidney transplantation from donors without a heartbeat. N. Engl. J. Med. 347, 248–255.

    PubMed  Google Scholar 

  45. Metcalfe M. S., Butterworth P. C., White S. A., et al. (2001) A case-control comparison of the results of renal transplantation from heart-beating and nonheart-beating donors. Transplantation 71, 1556–1559.

    CAS  PubMed  Google Scholar 

  46. Pirsch J. D., Ploeg R. J., Gange S., et al. (1996) Determinants of graft survival after renal transplantation. Transplantation 61, 1581–1586.

    CAS  PubMed  Google Scholar 

  47. Kootstra G. (1997) The asystolic, or non-heartbeating, donor. Transplantation 63, 917–921.

    CAS  PubMed  Google Scholar 

  48. Hume D. M., Merrill J. P., Miller B. F., and Thorn G. W. (1955) Experiences with renal homotransplantation in the human: report of nine cases. J. Clin. Invest. 34, 327–382.

    CAS  PubMed  Google Scholar 

  49. Starzl T. E., Marchioro T. L., Holmes J. H., et al. (1964) Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 55, 195–200.

    CAS  PubMed  Google Scholar 

  50. Slapak M., Naik R. B., and Lee H. A. (1981) Renal transplant in a patient with major donor-recipient blood group incompatibility: reversal of acute rejection by the use of modified plasmapheresis. Transplantation 31, 4–7.

    CAS  PubMed  Google Scholar 

  51. Alexandre G. P. J., Squifflet J. P., Bruyere M. D., et al. (1985) Splenectomy as a prerequisite for successful human ABO-incompatible renal transplantation. Transplant. Proc. 17, 138–143.

    Google Scholar 

  52. Takahashi K. (2001) ABO-Incompatible Kidney Transplantation, Elsevier Amsterdam.

    Google Scholar 

  53. Shishido S., Asanuma H., Tajima E., et al. (2001) ABO-incompatible livingdonor kidney transplantation in children. Transplantation 72, 1037–1042.

    CAS  PubMed  Google Scholar 

  54. Daniels G. (1995) Human Blood Groups, Blackwell Science, Oxford.

    Google Scholar 

  55. Nelson P. W., Landreneau M. D., Luger A. M., et al. (1998) Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation 65, 256–260.

    CAS  PubMed  Google Scholar 

  56. Schnuelle P. and van der Woude F. J. (1998) Should A2 kidneys be transplanted into B or O recipients?. Lancet 351, 1675–1676.

    CAS  PubMed  Google Scholar 

  57. Sells R. A. (1997) Paired-kidney-exchange programs. N. Engl. J. Med. 337, 1392–1393.

    CAS  PubMed  Google Scholar 

  58. Pleass H. C., Clark K. R., Rigg K. M., et al. (1995) Urologic complications after renal transplantation: a prospective randomized trial comparing different techniques of ureteric anastomosis and the use of prophylactic ureteric stents. Transplant Proc. 27, 1091–1092.

    CAS  PubMed  Google Scholar 

  59. Calne R. Y. (1987) Cyclosporin in cadaveric renal transplantation: 5-year follow-up of a multicentre trial. Lancet. 2, 506–507.

    CAS  PubMed  Google Scholar 

  60. Curtis J. J., Barbeito R., Pirsch J., Lewis R. M., Van Buren D. H., and Choudhury S. (1999) Differences in bioavailability between oral cyclosporine formulations in maintenance renal transplant patients. Am. J. Kidney Dis. 34, 869–874.

    CAS  PubMed  Google Scholar 

  61. Knoll G. A. and Bell R. C. (1999) Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 318, 1104–1107.

    CAS  PubMed  Google Scholar 

  62. Halloran P., Mathew T., Tomlanovich S., Groth C., Hooftman L., and Barker C. (1997) Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection.The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63, 39–47.

    CAS  PubMed  Google Scholar 

  63. Birkeland S. A. (2001) Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 71, 1089–1090.

    CAS  PubMed  Google Scholar 

  64. Ahsan N., Hricik D., Matas A., et al. (1999) Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 68, 1865–1874.

    CAS  PubMed  Google Scholar 

  65. Oberbauer R., Kreis H., Johnson R. W., et al.; Rapamune Maintenance Regimen Study Group. (2003) Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 76, 364–370.

    CAS  PubMed  Google Scholar 

  66. Watson C. J. (2001) Sirolimus (rapamycin) in clinical transplantation. Transplant. Rev. 15, 165–168.

    Google Scholar 

  67. Humar A., Kerr S., Gillingham K. J., and Matas A. J. (1999) Features of acute rejection that increase risk for chronic rejection. Transplantation 68, 1200–1203.

    CAS  PubMed  Google Scholar 

  68. Furness P. N., Philpott C. M., Chorbadjian M. T., et al. (2003) Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation 76, 969–973.

    PubMed  Google Scholar 

  69. Racusen L. C., Colvin R. B., Solez K., et al. (2003) Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am. J. Transplant. 3, 708–714.

    PubMed  Google Scholar 

  70. Racusen L. C., Solez K., Colvin R. B., et al. (1999) The Banff 97 working classification of renal allograft pathology. Kidney Int. 55, 713–723.

    CAS  PubMed  Google Scholar 

  71. Roberts I. S., Reddy S., Russell C., et al. (2004) Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. Transplantation 77, 1194–1198.

    PubMed  Google Scholar 

  72. Legendre C., Thervet E., Skhiri H., et al. (1998) Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 65, 1506–1509.

    CAS  PubMed  Google Scholar 

  73. Rush D., Nickerson P., Gough J., et al. (1998) Beneficial effects of treatment of early subclinical rejection: a randomized study. J. Am. Soc. Nephrol. 9, 2129–2134.

    CAS  PubMed  Google Scholar 

  74. Matas A. J., Gillingham K. J., Payne W. D., and Najarian J. S. (1994) The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 57, 857–859.

    CAS  PubMed  Google Scholar 

  75. Simon T., Opelz G., Wiesel M., Ott R. C., and Susal C. (2003) Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am. J. Transplant. 3, 1121–1127.

    CAS  PubMed  Google Scholar 

  76. Vasconcellos L. M., Schachter A. D., Zheng X. X., et al. (1998) Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 66, 562–566.

    CAS  PubMed  Google Scholar 

  77. Lederer S. R., Friedrich N., Regenbogen C., Getto R., Toepfer M., and Sitter T. (2003) Non-invasive monitoring of renal transplant recipients: urinary excretion of soluble adhesion molecules and of the complement-split product C4d. Nephron Clin. Pract. 94, 19–26.

    Google Scholar 

  78. Magee C. C., Denton M. D., Womer K. L., Khoury S. J., and Sayegh M. H. (2004) Assessment by flow cytometry of intracellular cytokine production in the peripheral blood cells of renal transplant recipients. Clin. Transplant. 18, 395–401.

    PubMed  Google Scholar 

  79. Hricik D. E., Rodriguez V., Riley J., et al. (2003) Enzyme linked immunosorbent spot (ELISPOT) atassay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am. J. Transplant. 3, 878–884.

    CAS  PubMed  Google Scholar 

  80. Gaber A. O., First M. R., Tesi R. J., et al. (1998) Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 66, 29–37.

    CAS  PubMed  Google Scholar 

  81. Midtvedt K., Fauchald P., Lien B., et al. (2003) Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection. Clin. Transplant. 17, 69–74.

    PubMed  Google Scholar 

  82. Casadei D. H., del Rial M., Opelz G., et al. (2001) A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 71, 53–58.

    CAS  PubMed  Google Scholar 

  83. Vincenti F., Kirkman R., Light S., et al. (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 338, 161–165.

    CAS  PubMed  Google Scholar 

  84. Nashan B., Moore R., Amlot P., Schmidt A. G., Abeywickrama K., and Soulillou J. P. (1997) Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350, 1193–1198.

    CAS  PubMed  Google Scholar 

  85. Chilcott J. B., Holmes M. W., Walters S., Akehurst R. L., and Nashan B. (2002) The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. Transplant. Int. 15, 486–493.

    Google Scholar 

  86. Lederer S. R., Kluth-Pepper B., Schneeberger H., Albert E., Land W., and Feucht H. E. (2001) Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int. 59, 334–341.

    CAS  PubMed  Google Scholar 

  87. Nickeleit V., Zeiler M., Gudat F., Thiel G., and Mihatsch M. J. (2002) Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J. Am. Soc. Nephrol. 13, 242–251.

    CAS  PubMed  Google Scholar 

  88. Mauiyyedi S., Crespo M., Collins A. B., et al. (2002) Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J. Am. Soc. Nephrol. 13, 779–787.

    PubMed  Google Scholar 

  89. Nickeleit V. and Mihatsch M. J. (2003) Kidney transplants, antibodies and rejection:is C4d a magic marker?. Nephrol. Dial. Transplant. 18, 2232–2239.

    CAS  PubMed  Google Scholar 

  90. Shah A., Nadasdy T., Arend L., et al. (2004) Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 77, 1399–1405.

    CAS  PubMed  Google Scholar 

  91. Vella J. P., O’Neill D., Atkins N., Donohoe J. F., and Walshe J. J. (1998) Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol. Dial. Transplant. 13, 2027–2032.

    CAS  PubMed  Google Scholar 

  92. Karpinski M., Pochinco D., Dembinski I., Laidlaw W., Zacharias J., and Nickerson P. (2004) Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J. Am. Soc. Nephrol. 15, 818–824.

    PubMed  Google Scholar 

  93. Doxiadis I. I., De Meester J., Smits J. M., et al. (1998) The impact of special programs for kidney transplantation of highly sensitized patients in Eurotransplant. Clin. Transplant. 115–120.

    Google Scholar 

  94. Duquesnoy R. J., Howe J., and Takemoto S. (2003) HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation 75, 889–897.

    CAS  PubMed  Google Scholar 

  95. Jordan S. C., Vo A., Bunnapradist S., et al. (2003) Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76, 631–636.

    CAS  PubMed  Google Scholar 

  96. Thibaudin D., Alamartine E., de Filippis J. P., Diab N., Laurent B., and Berthoux F. (1998) Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol. Dial. Transplant. 13, 711–715.

    CAS  PubMed  Google Scholar 

  97. Higgins R. M., Bevan D. J., Carey B. S., et al. (1996) Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 348, 208–1211.

    Google Scholar 

  98. Montgomery R. A., Zachary A. A., Racusen L. C., et al. (2000) Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch-positive recipients. Transplantation 70, 887–895.

    CAS  PubMed  Google Scholar 

  99. Brennan D. C. (2001) Cytomegalovirus in renal transplantation. J. Am. Soc. Nephrol. 12, 848–855.

    CAS  PubMed  Google Scholar 

  100. Hirsch H. H., and Steiger J. (2003) Polyomavirus BK. Lancet Infect. Dis. 3, 611–623.

    PubMed  Google Scholar 

  101. Kazory A., and Ducloux D. (2003). Renal transplantation and polyomavirus infection: recent clinical facts and controversies. Transplant. Infect. Dis. 5, 65–71.

    CAS  Google Scholar 

  102. Hirsch H. H., Knowles W., Dickenmann M.,et al. (2002) Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N. Engl. J. Med. 347, 488–496.

    PubMed  Google Scholar 

  103. Lin P. L., Vats A. N., and Green M. (2001) BK virus infection in renal transplant recipients. Pediatr. Transplant. 5, 398–405.

    CAS  PubMed  Google Scholar 

  104. Foley R. N., Parfrey P..S, and Sarnak M. J. (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32(5 Suppl. 3), S112–S119.

    CAS  PubMed  Google Scholar 

  105. Raine A. E., Margreiter R., Brunner F. P., et al. (1992) Report on management of renal failure in Europe, 22, 1991. Nephrol. Dial. Transplant. 7(Suppl. 2), 7–35.

    PubMed  Google Scholar 

  106. Kasiske B. L., Chakkera H. A., and Roel J. (2000) Explained and unexplained ischemic heart disease risk after renal transplantation. J. Am. Soc. Nephrol. 11, 1735–1743.

    CAS  PubMed  Google Scholar 

  107. Foley R. N. (2003) Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin. Dial. 16, 111–117.

    PubMed  Google Scholar 

  108. Holdaas H., Fellstrom B., Jardine A. G., et al.; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361, 2024–2031.

    CAS  PubMed  Google Scholar 

  109. Kwak B., Mulhaupt F., Myit S., and Mach F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med. 6, 1399–1402.

    CAS  PubMed  Google Scholar 

  110. Holdaas H. and Jardine A. (2003) Acute renal allograft rejections, a role for statins?. Minerva Urol. Nefrol. 55, 111–119.

    CAS  PubMed  Google Scholar 

  111. Kasiske B. L., Vazquez M. A., Harmon W. E., et al. (2000) Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J. Am. Soc. Nephrol. 11(Suppl. 15), S1–86.

    Google Scholar 

  112. EBPG Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.5.4. Cardiovascular risks. Post-transplant diabetes mellitus. Nephrol. Dial. Transplant. 17(Suppl. 4), 28

    Google Scholar 

  113. Ducloux D., Motte G., Challier B., Gibey R., and Chalopin J. M. (2000) Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J. Am. Soc. Nephrol. 11, 134–137.

    CAS  PubMed  Google Scholar 

  114. EBPG Expert Group on Renal Transplantation (2002). European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.5. Cardiovascular risks. Hyperhomocysteinaemia. Nephrol. Dial. Transplant. 17(Suppl. 4), 28.

    Google Scholar 

  115. Ducloux D., Kazory A., and Chalopin J. M. (2004) Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int. 66, 441–447.

    PubMed  Google Scholar 

  116. Roodnat J. I., Mulder P. G., Rischen-Vos J., van Riemsdijk I. C., van Gelder T., Zietse R., IJzermans J. N., and Weimar W. (2001) Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 72, 438–444.

    CAS  PubMed  Google Scholar 

  117. Bostom A. D., Brown R. S. Jr., Chavers B. M., et al. (2002) Prevention of posttransplant cardiovascular disease-report and recommendations of an ad hoc group. Am. J. Transplant. 2, 491–500.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wellcome Trust Research Training Fellow,University Department of Surgery, Addenbrooke’s Hospital, Cambridge, England

    Christopher J. Callaghan

  2. Department of Surgery, University of Cambridge, Cambridge, Cambridgeshire, England

    J. Andrew Bradley

Authors
  1. Christopher J. Callaghan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Andrew Bradley
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Heart and Lung Institute, London, UK

    Philip Hornick

  2. National Heart and Lung Institute, Harefield, UK

    Marlene Rose

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc.

About this protocol

Cite this protocol

Callaghan, C.J., Bradley, J.A. (2006). Current Status of Renal Transplantation. In: Hornick, P., Rose, M. (eds) Transplantation Immunology. Methods In Molecular Biology™, vol 333. Humana Press. https://doi.org/10.1385/1-59745-049-9:1

Download citation

  • DOI: https://doi.org/10.1385/1-59745-049-9:1

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-544-6

  • Online ISBN: 978-1-59745-049-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation